These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 15761193

  • 1. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
    Schäfer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, Bauersachs J.
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
    [Abstract] [Full Text] [Related]

  • 2. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A, Fraccarollo D, Vogt C, Flierl U, Hemberger M, Tas P, Ertl G, Bauersachs J.
    Biochem Pharmacol; 2007 May 01; 73(9):1367-75. PubMed ID: 17270148
    [Abstract] [Full Text] [Related]

  • 3. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
    Schäfer A, Fraccarollo D, Werner L, Bauersachs J.
    Pharmacol Res; 2010 Nov 01; 62(5):432-8. PubMed ID: 20600916
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer.
    Schäfer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J.
    Eur J Heart Fail; 2009 Apr 01; 11(4):336-41. PubMed ID: 19193626
    [Abstract] [Full Text] [Related]

  • 5. Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure.
    Schäfer A, Fraccarollo D, Pförtsch S, Loch E, Neuser J, Vogt C, Bauersachs J.
    Basic Res Cardiol; 2011 May 01; 106(3):485-94. PubMed ID: 21287353
    [Abstract] [Full Text] [Related]

  • 6. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo.
    Schäfer A, Alp NJ, Cai S, Lygate CA, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM.
    Arterioscler Thromb Vasc Biol; 2004 Sep 01; 24(9):1720-6. PubMed ID: 15242858
    [Abstract] [Full Text] [Related]

  • 7. Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats.
    Schäfer A, Widder J, Eigenthaler M, Ertl G, Bauersachs J.
    Biochem Pharmacol; 2004 Jun 15; 67(12):2273-9. PubMed ID: 15163558
    [Abstract] [Full Text] [Related]

  • 8. Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.
    Linz W, Itter G, Dobrucki LW, Malinski T, Wiemer G.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep 15; 4(3):180-5. PubMed ID: 14608524
    [Abstract] [Full Text] [Related]

  • 9. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
    Landsberger M, Jantzen F, Könemann S, Felix SB.
    Biochem Biophys Res Commun; 2005 Nov 04; 336(4):1005-9. PubMed ID: 16165089
    [Abstract] [Full Text] [Related]

  • 10. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A, Flierl U, Vogt C, Menninger S, Tas P, Ertl G, Bauersachs J.
    Pharmacol Res; 2007 Sep 04; 56(3):217-23. PubMed ID: 17669665
    [Abstract] [Full Text] [Related]

  • 11. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent.
    Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, Angermann CE, Ertl G, Bauersachs J.
    Cardiovasc Res; 2004 Jul 01; 63(1):161-7. PubMed ID: 15194473
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
    Schäfer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A, Walter U, Bauersachs J.
    Thromb Haemost; 2003 Jun 01; 89(6):1024-30. PubMed ID: 12783115
    [Abstract] [Full Text] [Related]

  • 13. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
    Piconi L, Corgnali M, Da Ros R, Assaloni R, Piliego T, Ceriello A.
    J Diabetes Complications; 2008 Jun 01; 22(1):38-45. PubMed ID: 18191076
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ, Lefer AM, Scalia R.
    Br J Pharmacol; 2001 Jun 01; 133(3):406-12. PubMed ID: 11375257
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
    Jantzen F, Könemann S, Wolff B, Barth S, Staudt A, Kroemer HK, Dahm JB, Felix SB, Landsberger M.
    J Physiol Pharmacol; 2007 Sep 01; 58(3):503-14. PubMed ID: 17928646
    [Abstract] [Full Text] [Related]

  • 20. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
    Sicard P, Lauzier B, Oudot A, Busseuil D, Collin B, Duvillard L, Moreau D, Vergely C, Rochette L.
    Arch Mal Coeur Vaiss; 2005 Sep 01; 98(7-8):804-8. PubMed ID: 16220751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.